Ipsen

EU regulators back Ipsen cancer drug in new liver cancer use

https://pharmaphorum.com/news/eu-regulators-cabometyx-liver/

Ipsen appoints new general manager for the UK & Ireland

https://pharmaphorum.com/news/ipsen-appoints-new-general-manager/

Scotland’s NHS to fund Ipsen cancer diarrhoea drug

https://pharmaphorum.com/news/scotlands-nhs-ipsen-cancer-drug/

EU approves Ipsen’s Cabometyx in first line kidney cancer

https://pharmaphorum.com/news/eu-approves-ipsens-cabometyx-in-first-line-kidney-cancer/

Ipsen takes on BMS as kidney cancer pill launches in EU

https://pharmaphorum.com/news/ipsens-opdivo-rival-off-the-mark-in-kidney-cancer/

NICE recommends funding for three thyroid cancer drugs

https://pharmaphorum.com/news/nice-recommends-funding-three-thyroid-cancer-drugs/

Hear from MedImmune and Ipsen at SMi’s Injectable Drug Delivery 2018

https://pharmaphorum.com/partner-content/hear-from-medimmune-and-ipsen-at-smis-injectable-drug-delivery-2018/

Ipsen aims for new liver cancer use of Cabometyx

https://pharmaphorum.com/news/ipsen-aims-new-liver-cancer-use-cabometyx/

Ipsen presents on oral peptides innovations, advances and delivery

https://pharmaphorum.com/partner-content/ipsen-presents-oral-peptides-innovations-advances-delivery/

1 2

Close in 10 seconds

Pharmaphorum.com

Search